Optimal duration of DAPT a continued focus of research

LONDON — In this video, Deepak L. Bhatt, MD, MPH, Chief Medical Editor of Cardiology Today’s Intervention, discusses results of the OPTIDUAL Hot Line trial of dual antiplatelet therapy after drug-eluting stent implantation and provides his opinion on future research to determine the optimal duration of therapy in this population.

The OPTIDUAL trial did not demonstrate superiority of 48-month dual antiplatelet therapy (DAPT) compared with 12-month DAPT for the primary outcome of net adverse cardiac events, according to results presented here. However, post-hoc analysis of ischemic outcomes revealed a borderline but not statistically significant reduction with extended DAPT.

Commenting on the findings, Bhatt, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School, said the data overall are “supportive of a longer vs. shorter duration of DAPT.” He noted that there is a further need for analysis of the OPTIDUAL trial as well as the larger, broader picture of trials evaluating shorter- vs. intermediate- vs. longer-term durations of DAPT. 

Источник: www.healio.com